Biodesix Test Predicts Response to Atezolizumab in Lung Cancer

Posted on



Download the PDF


Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018

 
BOULDER, Colo., Nov. 12, 2018 (GLOBE NEWSWIRE) Researchers with Biodesix® and Genentech, a member of the Roche Group, today presented findings on a test designed to predict response to atezolizumab (Tecentriq®) in patients with non-small cell lung cancer (NSCLC). The blood-based test, which uses expression data from the circulating proteome to classify patients, was found to be predictive for OS and PFS between atezolizumab and docetaxel. These data suggest a patient’s likelihood of benefiting from PD-L1 checkpoint inhibition can be identified through circulating proteome in blood samples. Researchers presented their findings at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C.
 
“Immunotherapy has become a standard of care in NSCLC and it is important to better understand the mechanisms of efficacy and resistance in patients,” said Heinrich Roder, D. Phil and CTO of Biodesix. “This study demonstrated the effectiveness of monitoring the proteome to identify patients who will receive optimal benefits from anti-PD-L1 therapy.”
 
The abstract presented at SITC 2018 can be found here on page 203.
 
The poster can be found here